Cardiovascular risk assessment using ASCVD risk score in fibromyalgia: a single-centre, retrospective study using

Sandeep Surendran1, C B Mithun1, Merlin Moni2

  • 1Department of Rheumatology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.

Insights

Fibromyalgia (FM) patients aged 40-59 show increased lifetime cardiovascular disease (CVD) risk. Machine learning models identified FM disease severity as a key CVD risk factor, improving risk prediction beyond traditional methods.

Area of Science:

  • Rheumatology
  • Cardiology
  • Data Science

Background:

  • Cardiovascular disease (CVD) risk assessment is crucial for autoimmune inflammatory rheumatological diseases.
  • Fibromyalgia (FM) patients face an elevated risk of CVD.
  • Integrating traditional risk assessment with Machine Learning (ML) can identify novel CVD risk factors in FM.

Purpose of the Study:

  • To assess cardiovascular disease (CVD) risk in fibromyalgia (FM) patients.
  • To develop and evaluate Machine Learning (ML) models for predicting CVD risk in FM.
  • To identify traditional and non-traditional CVD risk factors in FM patients.

Main Methods:

  • Retrospective case-control study involving 139 FM patients and 1820 controls.
  • Calculated 10-year and lifetime CVD risk using the ASCVD calculator.
  • Developed ML predictive models (random forest) for CVD risk, assessing accuracy, f1-score, and AUC.

Main Results:

  • FM patients aged 40-59 exhibited increased lifetime CVD risk (OR=1.56, p=0.043).
  • Conventional analysis did not link FM disease severity or duration to CVD risk.
  • ML models achieved high accuracy (95% for 10-year risk, 72% for lifetime risk) and identified FM disease severity as a significant contributor.

Conclusions:

  • Fibromyalgia patients aged 40-59 have a higher lifetime cardiovascular disease risk.
  • Machine learning models effectively identified fibromyalgia disease severity as a key predictor of CVD risk, complementing traditional factors.
  • ML holds potential for uncovering complex, non-linear risk factors in cardiovascular risk prediction for FM patients.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
63
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
119
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
510